Original Article
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3287-3300
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3287
Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells
Jun Wei, Zhong-Xin Zhao, Yang Li, Zhu-Qing Zhou, Tian-Geng You
Jun Wei, Zhong-Xin Zhao, Yang Li, Zhu-Qing Zhou, Tian-Geng You, Department of Gastroenterological Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
Author contributions: You TG and Zhao ZX designed the study; Wei J, Li Y and Zhou ZQ performed the experiments; Wei J and Zhou ZQ analyzed the data; Wei J wrote the paper; all of the authors contributed to the preparation of the manuscript.
Supported by Grants from the Project of Shanghai Science and Technology Commission of China, No. 10411968400
Correspondence to: Tian-Geng You, PhD, Department of Gastroenterological Surgery, Shanghai East Hospital, Tongji University School of Medicine, Jimo Rd 150, Shanghai 200120, China. tiangengyou2003@163.com
Telephone: +86-21-65982142 Fax: +86-21-58798999
Received: November 15, 2013
Revised: February 10, 2014
Accepted: March 6, 2014
Published online: March 28, 2014
Core Tip

Core tip: Cortactin is an actin-related protein 2/3 complex-activating and filamentous (F)-actin-binding protein that is implicated in tumor cell motility and metastasis. Clinical studies have shown that cortactin overexpression is often associated with the clinicopathological parameters and poor prognosis in a variety of cancers, including gastric cancer. In this study, the effects of cortactin on gastric cancer progression were investigated. The results showed that cortactin expression promoted SGC-7901 cell migration, invasion and proliferation both in vitro and in vivo. The epidermal growth factor receptor signaling pathway is mechanistically involved. Cortactin may serve as a novel therapeutic target of gastric cancer.